AIMS: Cannabinoid CB(2) agonists have been shown to alleviate behavioral signs of inflammatory and neuropathic pain in animal models. AM1241, a CB(2) agonist, does not demonstrate central nervous system side effects seen with CB(1) agonists such as hypothermia and catalepsy. Metastatic bone cancer causes severe pain in patients and is treated with analgesics such as opiates. Recent reports suggest that sustained opiates can produce paradoxical hyperalgesic actions and enhance bone destruction in a murine model of bone cancer. In contrast, CB(2) selective agonists have been shown to reduce bone loss associated with a model of osteoporosis. Here we tested whether a CB(2) agonist administered over a 7day period inhibits bone cancer-induced pain as well as attenuates cancer-induced bone degradation. MAIN METHODS: A murine bone cancer model was used in which osteolytic sarcoma cells were injected into the intramedullary space of the distal end of the femur. Behavioral and radiographic image analysis was performed at days 7, 10 and 14 after injection of tumor cells into the femur. KEY FINDINGS: Osteolytic sarcoma within the femur produced spontaneous and touch evoked behavioral signs of pain within the tumor-bearing limb. The systemic administration of AM1241 acutely or for 7days significantly attenuated spontaneous and evoked pain in the inoculated limb. Sustained AM1241 significantly reduced bone loss and decreased the incidence of cancer-induced bone fractures. SIGNIFICANCE: These findings suggest a novel therapy for cancer-induced bone pain, bone loss and bone fracture while lacking many unwanted side effects seen with current treatments for bone cancer pain.
AIMS: Cannabinoid CB(2) agonists have been shown to alleviate behavioral signs of inflammatory and neuropathic pain in animal models. AM1241, a CB(2) agonist, does not demonstrate central nervous system side effects seen with CB(1) agonists such as hypothermia and catalepsy. Metastatic bone cancer causes severe pain in patients and is treated with analgesics such as opiates. Recent reports suggest that sustained opiates can produce paradoxical hyperalgesic actions and enhance bone destruction in a murine model of bone cancer. In contrast, CB(2) selective agonists have been shown to reduce bone loss associated with a model of osteoporosis. Here we tested whether a CB(2) agonist administered over a 7day period inhibits bone cancer-induced pain as well as attenuates cancer-induced bone degradation. MAIN METHODS: A murinebone cancer model was used in which osteolytic sarcoma cells were injected into the intramedullary space of the distal end of the femur. Behavioral and radiographic image analysis was performed at days 7, 10 and 14 after injection of tumor cells into the femur. KEY FINDINGS:Osteolytic sarcoma within the femur produced spontaneous and touch evoked behavioral signs of pain within the tumor-bearing limb. The systemic administration of AM1241 acutely or for 7days significantly attenuated spontaneous and evoked pain in the inoculated limb. Sustained AM1241 significantly reduced bone loss and decreased the incidence of cancer-induced bone fractures. SIGNIFICANCE: These findings suggest a novel therapy for cancer-induced bone pain, bone loss and bone fracture while lacking many unwanted side effects seen with current treatments for bone cancer pain.
Authors: Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; Lawrence J Marnett; Vincenzo Di Marzo; Quentin J Pittman; Kamala D Patel; Keith A Sharkey Journal: Science Date: 2005-10-14 Impact factor: 47.728
Authors: Emmanuel S Onaivi; Hiroki Ishiguro; Patel Sejal; Paul A Meozzi; Lester Myers; Patricia Tagliaferro; Bruce Hope; Claire M Leonard; George R Uhl; Alicia Brusco; Eileen Gardner Journal: Methods Mol Med Date: 2006
Authors: Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini Journal: Cancer Cell Date: 2005-09 Impact factor: 31.743
Authors: Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga Journal: J Neuroimmunol Date: 2012-01-30 Impact factor: 3.478
Authors: Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch Journal: Neuropsychopharmacology Date: 2015-10-30 Impact factor: 7.853
Authors: Iryna A Khasabova; James Gielissen; Anisha Chandiramani; Catherine Harding-Rose; Desiree Abu Odeh; Donald A Simone; Virginia S Seybold Journal: Behav Pharmacol Date: 2011-09 Impact factor: 2.293
Authors: Alysia N Lozano-Ondoua; Katherine E Hanlon; Ashley M Symons-Liguori; Tally M Largent-Milnes; Josh J Havelin; Henry L Ferland; Anupama Chandramouli; Mabel Owusu-Ankomah; Tijana Nikolich-Zugich; Aaron P Bloom; Juan Miguel Jimenez-Andrade; Tamara King; Frank Porreca; Mark A Nelson; Patrick W Mantyh; Todd W Vanderah Journal: J Bone Miner Res Date: 2013-01 Impact factor: 6.741
Authors: Jodianne T Wood; Dustin M Smith; David R Janero; Alexander M Zvonok; Alexandros Makriyannis Journal: Life Sci Date: 2012-06-28 Impact factor: 5.037